Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy
Status:
Not yet recruiting
Trial end date:
2026-07-01
Target enrollment:
Participant gender:
Summary
The TaRGET study is a multi-centre, prospective, randomized, double-blind, placebo-controlled
trial designed to evaluate the potential therapeutic efficacy of tideglusib, a glycogen
synthase kinase-3 β inhibitor, in genotype positive arrhythmogenic cardiomyopathy.
Phase:
Phase 2
Details
Lead Sponsor:
Hamilton Health Sciences Corporation
Collaborators:
AMO Pharma Canadian Institutes of Health Research (CIHR) Canadian SADS Hearts in Rhythm Organization (HiRO) Population Health Research Institute